mjn-neuro

MJN Neuroserveis operates at the intersection of medical devices, neurotechnology, and digital health, focusing on EEG-based monitoring outside conventional hospital settings. Its clearest differentiation is the combination of a wearable ear sensor, brain-signal analysis, and connected mobile alerts for people at elevated risk of epileptic seizures. The company also describes mjn-DREAMER, an EEG and cognitive-testing approach for Alzheimer’s-related screening and monitoring, and mjn-VISOR, an ambulatory EEG system. The market includes medical-device and digital-health developers addressing seizure detection, EEG monitoring, and remote neurological care; MJN’s stated distinction is its ear-worn form factor and connection to patient and caregiver alerts. Its scale appears small, with an employee range of 1–10, and its financing history includes grants, seed funding, crowdfunding, and venture rounds rather than a large disclosed institutional equity raise. This profile suggests a specialized early-stage company, not evidence of market leadership.

MJN Neuroserveis was founded in 2014 and has developed a focused portfolio of wearable and EEG-based neurological products. Its financing history includes equity crowdfunding of approximately $714,817 in 2017, a $185,891 seed round in 2018, and a $2,548,918 venture round in January 2021. A further venture round in December 2020 and a grant in March 2021 are listed without USD amounts. Total funding is reported as $3,449,626, while the company’s employee range is 1–10. A key potential inflection point came with the Nov 27, 2025 announcement alongside Neuraxpharm of plans to launch EPISERAS in Europe, with July 2026 identified as the target timing. Overall, the company’s trajectory shows product development and partnership activity, while its next growth phase depends on demonstrating deployment, clinical adoption, and repeatable commercialization.